Progyny (NASDAQ:PGNY) Stock: Insider Peter Anevski Sells 11,939 Shares

Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski sold 11,939 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $35.13, for a total transaction of $419,417.07. Following the sale, the chief executive officer directly owned 797,572 shares of the company’s stock, valued at approximately $28,018,704.36. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Anevski also recently made the following trade(s):

• On Monday, November 9th, Peter Anevski sold 161,308 shares of Progyny stock. The shares were sold at an average price of $35.73, for a total transaction of $5,763,534.84.

Progyny Trading Up 3.2%

Progyny stock traded up $1.11 on Monday, reaching $35.95. 1,645,331 shares of the stock were exchanged, compared to its average volume of 914,017. The stock has a market cap of $2.76 billion, a PE ratio of 32.98, a PEG ratio of 2.08 and a beta of 0.97. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $36.00. The firm has a fifty day moving average price of $27.65 and a two-hundred day moving average price of $24.64.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. The company had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.23%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.15 earnings per share. Equities analysts anticipate that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PGNY shares. Leerink Partners raised their target price on Progyny from $37.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday. Citizens Jmp increased their price objective on Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a research report on Thursday. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. BTIG Research boosted their target price on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Finally, Citigroup reiterated a “market outperform” rating on shares of Progyny in a research note on Thursday. Eleven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Institutional Trading of Progyny

Institutional investors and hedge funds have recently modified their holdings of the company. Toth Financial Advisory Corp raised its stake in shares of Progyny by 21.3% in the third quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock valued at $69,000 after purchasing an additional 480 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Progyny by 14.4% during the third quarter. Hantz Financial Services Inc. now owns 4,124 shares of the company’s stock worth $104,000 after buying an additional 520 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Progyny by 4.2% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock valued at $435,000 after buying an additional 700 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Progyny in the 2nd quarter valued at $29,000. Finally, State of Wyoming raised its stake in shares of Progyny by 3.5% in the 3rd quarter. State of Wyoming now owns 29,806 shares of the company’s stock valued at $751,000 after buying an additional 1,015 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment.

The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.

Founded in 2008, Progyny serves employer clients and their workforces in the United States.